CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Chief Executive Officer acquired 60,000 shares (option exercise)
- 4 Exercise or conversion COO & Chief Financial Officer acquired 30,000 shares (option exercise)
- 4 Open-market buy Chief Scientific Officer bought 763 shares at $14.40 ($10,987)
- 4 Open-market sale Director sold 1,000 shares at $88.93 ($88,930)
- 4 Open-market sale COO & Chief Financial Officer sold 4,963 shares at $98.50 ($488,856)
- 4 Open-market sale Director sold 6,000 shares at an average $95.44 ($572,644)
- 4 Open-market sale COO & Chief Financial Officer sold 22,000 shares at an average $95.31 ($2,096,779)
- 4 Open-market sale Chief Medical Officer sold 10,000 shares at $100.00 ($1,000,000)
- 4 Open-market sale Chief Medical Officer sold 58,261 shares at an average $54.04 ($3,148,172)
- 4 Open-market sale COO & Chief Financial Officer sold 20,000 shares at an average $54.15 ($1,083,074)
- 4 Open-market sale Director sold 550 shares at an average $55.15 ($30,333)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Executive Officer sold 30,000 shares at an average $34.58 ($1,037,361)
Page 7 of 11 · 211 filings